← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck Sharp & Dohme

FDA approvalNew or expanded indicationBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors, who could not undergo or chose not to undergo cystectomy.

LAMPGEN ANALYSIS

Why it matters

Added a systemic immunotherapy option for patients with persistent high-risk disease considering bladder preservation.

What research teams should watch

Document prior BCG courses and surgical eligibility; standardize cystoscopy and cytology schedules.

PRIMARY RECORDS

Sources